title: [Experience using veroshpiron in the combined therapy of parkinsonism].
abstract: The authors found changes in the function of the adrenals in parkinsonism, which were expressed in the form of elevated excretion of aldosterone and diminished excretion of hydrocortisone. The use of veroshpiron led to a certain normalization of adrenal function and to activation of the sympatho-adrenal system. The study of the clinical efficacy of veroshpiron administered for 20 days in a daily dose of 50-100 mg to 56 patients with parkinsonism showed improvement of a varying degree in 87.5% of patients. A 20-day course of veroshpiron resulted in regression of approximately 1/3 of the main symptoms of parkinsonism with the improvement persisting for several months.
authors.forename: K Z
authors.initials: KZ
authors.lastname: Vartanian
authors.forename: M Kh
authors.initials: MKh
authors.lastname: Karimova
mesh_terms: D000311:Adrenal Glands / Q000187:drug effects; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002395:Catecholamines / Q000652:urine; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000652:urine; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000652:urine; D013148:Spironolactone / Q000627:therapeutic use*; D013564:Sympathetic Nervous System / Q000187:drug effects
chemical_list: D000978:Antiparkinson Agents; D002395:Catecholamines; D005938:Glucocorticoids; D010276:Parasympatholytics; D013148:Spironolactone; D007980:Levodopa
vernacular_title: Opyt primeneniia veroshpirona v kompleksnoĭ terapii parkinsonizma.